ASS1 regulates immune microenvironment via CXCL8 signaling in ovarian cancer.
記録の確認項目
- 研究デザイン
- その他の原著論文
- 対象
- ヒト・動物 併記
- 出版年
- 2022
- 出典
- doi.org
- 抄録の表示
- 表示あり
- 出版状態
- 有効な記録
- 状態確認日
- 2026/08/17
- 収集日
- 2026/08/13
- 鮮度
- 確認期限内
- 確認段階
- 自動処理
- 記録状態
- 公開
抄録
Ovarian cancer is one of the most serious and deadly cancers for female and currently no effective screening approaches have been achieved. Therefore it is usually diagnosed at an advanced stage and most patients have a poor prognosis. The development of ovarian cancer is a comprehensive process depending on the cross-talk between the various cells in the tumor microenvironment and the immune system. Thus, the immunotherapy may be revolutionized as an effective treatment of this disease. In this study, we firstly identified ASS1 as an immunomodulatory molecule. By RNA sequencing, antibody array and animal assys, we further provided new insights into understanding the crosstalk between ovarian cancer cells and their microenvironmental immune molecules , which may suggest a new potential therapeutic target for ovarian cancer.
MeSH
DOI 10.1016/j.bbrc.2022.08.045
PMID 36182868
原文・出典を見る →